Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Danish Headache Center
There remains a great need for more effective anti-migraine drugs with fewer side effects. Human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. The investigators' group has shown that Calcitonine Gene Related Peptide (CGRP) induce headache/migraine in both healthy volunteers and in patients with migraine without aura (MO). To validate this model, the headache must respond to specific migraine treatment with sumatriptan.
Hypothesis: CGRP induces a migraine-like headache in both healthy subjects and in MO-patients and induced headache responds to a specific anti migraine drug; sumatriptan.
Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs.
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy:
Healthy subjects of both sexes Age 18-60 years Weight 45-95 kg. Females were requested to use effective contraception.
Migraine patients:
Migraine patients who meet IHS criteria for migraine with or without aura of both sexes 18-60 years 45-95 kg.
You may not be if
Healthy:
Any type of headache (except episodic tension-type headache \< 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives).
Migraine patients:
Any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives) Triptan non-responders
